The AIM-quoted firm isn’t moving too far though; it is staying at the Babraham Research Campus where it previously ran its UK operations from two buildings.
Move to be fully completed this month
All of the operations – including head office functions and biology and chemistry research services – are currently being consolidated into the new, larger building. That process is expected to be completed by the end of this month (January).
The new facility has been purpose-built to suit the company’s needs and allows all of the UK-based science teams to work together in a single, state-of-the-art facility.
Abzena has also entered into an agreement with Babraham Bioscience Technologies – the company which develops and manages the campus – to develop the antibody discovery services formerly provided by BBT’s technology development laboratory.
Lease signed for San Diego facility
Over in the US, Abzena has now signed a long-term lease for a new 50,000 square feet facility in San Diego which will bring all of its west coast biomanufacturing operations under one roof.
First to move into the new building will be the process and analytical development groups from the existing labs in Torrey Pines. They are expected to move in the second quarter of this year.
Further remodelling of the building will be required before the manufacturing division can relocate, but the facility should be fully operational early next year.
Abzena has hired Sartorius Stedim Biotech which will fit out the building with the necessary equipment, software and provide support for the design of the new biomanufacturing facility in San Diego.
Anzena is also in the process of building a GMP conjugation suite at its factory in Bristol, Pennsylvania which is on track to be ready by the end of the current quarter.
‘Important strategic step’
“The new facilities in Cambridge and San Diego are an important strategic step in the delivery of our integrated services model and will greatly enhance Abzena's operations,” said chief executive John Burt.
“The combination of state-of-the-art facilities and leading technologies will enable the group to support its international customers as they progress their drug development programmes from research into clinical trials.”